Antimicrobial susceptibility of clinical isolates of non-jejuni/coli campylobacters and arcobacters from Belgium
Authors:
- Olivier VandenbergOVOlivier Vandenberg
- Kurt HoufKHKurt Houf
- Nicole DouatNDNicole Douat
- Linda VlaesLVLinda Vlaes
- Patricia RetorePRPatricia Retore
- Jean-Paul ButzlerJBJean-Paul Butzler
- Anne DedisteADAnne Dediste
Open Access
- 13 March 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (5) , 908-913
Abstract
Objectives: To determine the susceptibility of non-jejuni/coli campylobacters and arcobacters isolated from diarrhoeal stool specimens in Belgium. Methods: The MICs were determined using Etest for six antimicrobial agents including ampicillin, erythromycin, nalidixic acid, ciprofloxacin, gentamicin and tetracycline for the most frequently isolated non-jejuni/coli campylobacter and arcobacter strains in two University Hospital laboratories between 1995 and 2005. Results: In total, 85 Campylobacter upsaliensis, 20 Campylobacter concisus, 11 Campylobacter fetus, 61 Arcobacter butzleri and 10 Arcobacter cryaerophilus isolates were tested. Most C. upsaliensis strains were susceptible to ampicillin (100%), gentamicin (100%), ciprofloxacin (94.1%) and tetracycline (100%), whereas 11.8 and 12.9% were resistant to nalidixic acid and erythromycin, respectively. For A. butzleri, 78.7% of isolates were susceptible to ampicillin and erythromycin. Most A. butzleri isolates were susceptible to ciprofloxacin (96.7%), nalidixic acid (82.0%), gentamicin (100%) and tetracycline (100%). All C. concisus strains were fully susceptible to ampicillin and tetracycline, but 5% of them were resistant to gentamicin, ciprofloxacin and erythromycin. Nearly all C. fetus and A. cryaerophilus strains were susceptible to erythromycin but the results should be interpreted with caution since only a small number of strains were tested. Conclusions: Fluoroquinolones should be considered in the treatment of severe C. upsaliensis and A. butzleri infection. When clinically indicated, erythromycin remains the first choice for the treatment of intestinal campylobacteriosis caused by C. concisus and C. fetus.Keywords
This publication has 30 references indexed in Scilit:
- Antimicrobial resistance patterns of Campylobacter from feedlot cattle*Journal of Applied Microbiology, 2005
- Campylobacter concisus: an evaluation of certain phenotypic and genotypic characteristicsClinical Microbiology and Infection, 2005
- Antimicrobial Susceptibility Patterns of Arcobacter butzleri and Arcobacter cryaerophilus Strains Isolated from Humans and BroilersMicrobial Drug Resistance, 2004
- Development of a Standardized Susceptibility Test for Campylobacter with Quality-Control Ranges for Ciprofloxacin, Doxycycline, Erythromycin, Gentamicin, and MeropenemMicrobial Drug Resistance, 2004
- Epidemiology and Antimicrobial Susceptibilities of 111 Campylobacter fetus subsp. fetus Strains Isolated in Québec, Canada, from 1983 to 2000Journal of Clinical Microbiology, 2003
- Campylobacter upsaliensis:Another Pathogen for Consideration in the United StatesClinical Infectious Diseases, 2002
- Campylobacter jejuni— An Emerging Foodborne PathogenEmerging Infectious Diseases, 1999
- A selective medium for the isolation of Arcobacter from meatsLetters in Applied Microbiology, 1996
- Taxonomy of Campylobacter, Arcobacter, and Helicobacter: A ReviewZentralblatt für Bakteriologie, 1992
- In vitro susceptibility of“Campylobacter upsaliensis” to twenty-four antimicrobial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990